Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Besivo in Renal Impairment
NCT04249908Phase 1Unknown
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Feb 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of adefovir dipivoxil in Chronic Hepatitis B (CHB) (4 arms), sponsored by Ildong Pharmaceutical Co Ltd. Primary endpoints: Area under the plasma concentration-time curve (AUC)_0-t up to 72 hours and Maximum plasma concentration up to 72 hours. Status: unknown.
02
Drugs
adefovir dipivoxil
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04249908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04249908.